baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Galera Therapeutics/ US36338D1081 /

24/05/2024 21:46:07	Chg. +0.02	Volume	Bid-	Ask-	High	Low
0.19USD	+10.46%	4,055 Turnover: 759.17	-Bid Size: -	-Ask Size: -	0.19	0.18

GlobeNewswire 13/05 Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

GlobeNewswire 03/05 Galera Adopts Limited Duration Stockholder Rights Agreement

GlobeNewswire 16/04 Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.

GlobeNewswire 28/03 Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

GlobeNewswire 14/11/2023 Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

GlobeNewswire 31/10/2023 Galera Announces Receipt of Type A Meeting Minutes and Strategic Update

GlobeNewswire 18/09/2023 Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem

GlobeNewswire 05/09/2023 Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire 10/03/2022 Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates

GlobeNewswire 05/01/2022 Context Therapeutics® Strengthens Research & Development Team

GlobeNewswire 14/12/2021 Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of...

GlobeNewswire 15/11/2021 Galera to Present at Two Upcoming Investor Conferences in November

GlobeNewswire 10/11/2021 Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

GlobeNewswire 19/10/2021 Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral M...

GlobeNewswire 12/10/2021 Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Lega...

GlobeNewswire 14/09/2021 Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) ...

GlobeNewswire 08/09/2021 Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Par...

GlobeNewswire 07/09/2021 Galera to Present at Three Upcoming Investor Conferences in September

GlobeNewswire 10/08/2021 Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments

GlobeNewswire 28/06/2021 Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Sev...

GlobeNewswire 26/05/2021 Galera to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire 17/05/2021 Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreat...

GlobeNewswire 12/05/2021 Science Translational Medicine Article Shows Galera’s Selective Dismutase Mimetic Synergizes with Ra...

GlobeNewswire 11/05/2021 Galera Reports First Quarter 2021 Financial Results and Recent Accomplishments

GlobeNewswire 05/05/2021 Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference

Galera Therapeutics/ US36338D1081 /

If you wish to receive reply to your feedback, please provide your email address.